Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.

Cancer medicine

Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J.
PMID: 29436178
Cancer Med. 2018 Mar;7(3):746-756. doi: 10.1002/cam4.1372. Epub 2018 Feb 13.

Microsatellite instability (MSI) testing identifies patients who may benefit from immune checkpoint inhibitors. We developed an MSI assay that uses data from a commercially available next-generation sequencing (NGS) panel to determine MSI status. The assay is applicable across cancer...

Cite
Vanderwalde A, Spetzler D, Xiao N, et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018;7(3):746-756doi: 10.1002/cam4.1372.
Vanderwalde, A., Spetzler, D., Xiao, N., Gatalica, Z., & Marshall, J. (2018). Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer medicine, 7(3), 746-756. https://doi.org/10.1002/cam4.1372
Vanderwalde, Ari, et al. "Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients." Cancer medicine vol. 7,3 (2018): 746-756. doi: https://doi.org/10.1002/cam4.1372
Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018 Mar;7(3):746-756. doi: 10.1002/cam4.1372. Epub 2018 Feb 13. PMID: 29436178; PMCID: PMC5852359.
Copy Download .nbib Format: NLM
[Impact of PD-L1 status on the long-term outcomes of radical treatment of patients with prostate cancer].

Urologiia (Moscow, Russia : 1999)

Matveev VB, Kirichek AA, Safronova VM, Khafizov KO, Filippova MG, Lyubchenko LN.
PMID: 31535805
Urologiia. 2019 Sep;(4):51-57.

A wide range of variables are associated with poor long-term outcomes of radical treatment in patients with prostate cancer (PCa). Expression of the programmed death-1 ligand 1 (PD-L1) in tumor might be a potential novel marker for PCa.AIM: to...

Cite
Matveev VB, Kirichek AA, Safronova VM, et al. [Impact of PD-L1 status on the long-term outcomes of radical treatment of patients with prostate cancer]. Urologiia. 2019;(4):51-57
Matveev, V. B., Kirichek, A. A., Safronova, V. M., Khafizov, K. O., Filippova, M. G., & Lyubchenko, L. N. (2019). [Impact of PD-L1 status on the long-term outcomes of radical treatment of patients with prostate cancer]. Urologiia (Moscow, Russia : 1999), (4), 51-57.
Matveev, V B, et al. "[Impact of PD-L1 status on the long-term outcomes of radical treatment of patients with prostate cancer]." Urologiia (Moscow, Russia : 1999) vol. ,4 (2019): 51-57.
Matveev VB, Kirichek AA, Safronova VM, Khafizov KO, Filippova MG, Lyubchenko LN. [Impact of PD-L1 status on the long-term outcomes of radical treatment of patients with prostate cancer]. Urologiia. 2019 Sep;(4):51-57. Russian. PMID: 31535805.
Copy Download .nbib Format: NLM
PD-L1 Expression in Small Cell Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Yasuda Y, Ozasa H, Kim YH.
PMID: 29472058
J Thorac Oncol. 2018 Mar;13(3):e40-e41. doi: 10.1016/j.jtho.2017.10.013.

No abstract available.

Cite
Yasuda Y, Ozasa H, Kim YH. PD-L1 Expression in Small Cell Lung Cancer. J Thorac Oncol. 2018;13(3):e40-e41doi: 10.1016/j.jtho.2017.10.013.
Yasuda, Y., Ozasa, H., & Kim, Y. H. (2018). PD-L1 Expression in Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13(3), e40-e41. https://doi.org/10.1016/j.jtho.2017.10.013
Yasuda, Yuto, et al. "PD-L1 Expression in Small Cell Lung Cancer." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 13,3 (2018): e40-e41. doi: https://doi.org/10.1016/j.jtho.2017.10.013
Yasuda Y, Ozasa H, Kim YH. PD-L1 Expression in Small Cell Lung Cancer. J Thorac Oncol. 2018 Mar;13(3):e40-e41. doi: 10.1016/j.jtho.2017.10.013. PMID: 29472058.
Copy Download .nbib Format: NLM
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.

Trends in biochemical sciences

Zhang J, Dang F, Ren J, Wei W.
PMID: 30287140
Trends Biochem Sci. 2018 Dec;43(12):1014-1032. doi: 10.1016/j.tibs.2018.09.004. Epub 2018 Oct 01.

PD-L1, frequently expressed in human cancers, engages with PD-1 on immune cells and contributes to cancer immune evasion. As such, antibodies blocking the PD-1/PD-L1 interaction reactivate cytotoxic T cells to eradicate cancer cells. However, a majority of cancer patients...

Cite
Zhang J, Dang F, Ren J, et al. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends Biochem Sci. 2018;43(12):1014-1032doi: 10.1016/j.tibs.2018.09.004.
Zhang, J., Dang, F., Ren, J., & Wei, W. (2018). Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends in biochemical sciences, 43(12), 1014-1032. https://doi.org/10.1016/j.tibs.2018.09.004
Zhang, Jinfang, et al. "Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy." Trends in biochemical sciences vol. 43,12 (2018): 1014-1032. doi: https://doi.org/10.1016/j.tibs.2018.09.004
Zhang J, Dang F, Ren J, Wei W. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends Biochem Sci. 2018 Dec;43(12):1014-1032. doi: 10.1016/j.tibs.2018.09.004. Epub 2018 Oct 01. PMID: 30287140; PMCID: PMC6252278.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries